Versono Medical Ltd.

Based in Galway, Ireland, and founded in 2018, Versono Medical Ltd. a new technology platform for endovascular surgery to treat Complex Chronic Lesions. The company was founded by Finbar Dolan and Hugh O'Donoghue. The company has reached partnerships with global clinicians and research institutions since its establishment.

In May 2022, Versono Medical Ltd. raised EUR 6. 7 million in venture funding from new investors Enterprise Ireland and Western Development Commission, with participation from returning investors Business Venture Partners and DHKN Limited. Individual investors also participated in the round.

As of 2022, the company has 22 employees in force. The company's medication developing focus is on Critical limb ischemia (CLI), and Peripheral Arterial Disease (PAD). The company develops an intravascular ultrasonic platform technology, which can be used to treat CLI. CLI is a kind of disease that affects the legs and feet, and can lead to calcified tissue and chronic blockages that require technically difficult procedures.

The company will utilize the fund raised in 2022 to move its product trials forward and expand its team size. The funding will also allow Versono to complete clinical studies and to qualify strategic medical device technology in 2023, for its initial clinical indication to cross arterial blockages and carry therapies to treat blockages.